- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.10. | Ernexa Therapeutics Inc.: Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa | 1 | GlobeNewswire (USA) | ||
| 29.09. | Ernexa Therapeutics: Interview With President & CEO Sanjeev Luther About The Innovative Cell Therapy Company | 2 | pulse2.com | ||
| 29.09. | Ernexa Therapeutics Inc.: Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit | 1 | GlobeNewswire (USA) | ||
| 10.09. | Ernexa Therapeutics reports 51% reduction in operating expenses | 1 | Investing.com | ||
| 10.09. | Ernexa Therapeutics senkt operative Kosten um 51 % | - | Investing.com Deutsch | ||
| 10.09. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Provides Update on Operational Excellence and Performance | 213 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today provided... ► Artikel lesen | |
| 13.08. | Ernexa Therapeutics Inc. - 10-Q, Quarterly Report | 5 | SEC Filings | ||
| 09.07. | Ernexa regains Nasdaq compliance, continues trading on exchange | 2 | Investing.com | ||
| ERNEXA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 09.07. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements | 267 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced... ► Artikel lesen | |
| 07.07. | Biotech-Unternehmen Ernexa Therapeutics beauftragt Haskell & White als neuen Wirtschaftsprüfer | 1 | Investing.com Deutsch | ||
| 07.07. | Ernexa Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.06. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development | 2 | GlobeNewswire (USA) | ||
| 24.06. | Ernexa Therapeutics completes second closing of securities offering | 1 | Investing.com | ||
| 24.06. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement | 1 | GlobeNewswire (USA) | ||
| 12.06. | Ernexa Therapeutics kündigt Aktienzusammenlegung im Verhältnis 1:15 an | 3 | Investing.com Deutsch | ||
| 11.06. | Ernexa Therapeutics registers 57M shares for resale | 2 | Seeking Alpha | ||
| 11.06. | Ernexa Therapeutics Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 10.06. | Ernexa Announces 1-for-15 Reverse Stock Split Effective June 12 To Regain Nasdaq Compliance | - | RTTNews | ||
| 10.06. | Ernexa Therapeutics announces 1-for-15 reverse stock split | 1 | Investing.com | ||
| 10.06. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split | 246 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced... ► Artikel lesen |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ARCUTIS BIOTHERAPEUTICS | 20,050 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 | ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere... ► Artikel lesen | |
| 89BIO | 14,800 | 0,00 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,305 | 0,00 % | RECURSION PHARMACEUTICALS INC zündet den Turbo jetzt! | ||
| BEAM THERAPEUTICS | 26,340 | 0,00 % | Jefferies stuft Beam Therapeutics auf "Buy": Kommende Katalysatoren im Fokus | ||
| BIONTECH | 89,35 | +1,71 % | BioNTech Aktie zeigt Stärke: Es wird spannend! | Seit dem letzten 4investors.de-Chartcheck zur BioNTech Aktie hat sich einiges getan. Der Aktienkurs des Mainzer Biotech-Konzerns ist an der NASDAQ um rund 9 Dollar gestiegen, hat die 20- und 50-Tage-Linie... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 10,290 | 0,00 % | Oppenheimer senkt Kursziel für Moonlake Immunotherapeutics nach durchwachsenen Studienergebnissen | ||
| LENZ THERAPEUTICS | 38,740 | 0,00 % | Piper Sandler raises LENZ Therapeutics stock price target to $67 on VIZZ launch | ||
| MINERALYS THERAPEUTICS | 42,170 | +7,06 % | Mineralys Therapeutics: Aktie erreicht Rekordhoch von 41,11 USD | ||
| EVOTEC | 6,658 | -0,60 % | Evotec Aktie: Strohfeuer oder klappt es diesmal? | Die Evotec Aktie zeigt Stärke - aber diesmal auch für eine längere Zeit? Seit dem 26. September hat sich die TecDAX-notierte Biotech-Aktie von 5,882 Euro um mehr als einen Euro verteuert. Am gestrigen... ► Artikel lesen | |
| ARCELLX | 86,80 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 52,45 | 0,00 % | Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million | SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for... ► Artikel lesen | |
| QIAGEN | 40,535 | +0,16 % | Sysmex, QIAGEN Announce Exclusive Distribution Partnership For Diagnostic Products In Japan | TOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) and QIAGEN K.K., the Japanese subsidiary of QIAGEN N.V., announced on Wednesday that they have entered into a partnership for clinical diagnostic... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 49,740 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,320 | -5,87 % | UBS bestätigt Kaufempfehlung für Summit Therapeutics vor ESMO-Daten | ||
| COGENT BIOSCIENCES | 16,250 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WALTHAM, Mass. and BOULDER, Colo., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen |
Das Unternehmen ERNEXA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,360 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ERNEXA THERAPEUTICS INC finden Sie auf Wallstreet Online.